X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (21) 21
human necessities (18) 18
hygiene (18) 18
medical or veterinary science (18) 18
preparations for medical, dental, or toilet purposes (18) 18
male (17) 17
female (16) 16
middle aged (16) 16
prasugrel hydrochloride (15) 15
aged (13) 13
ticlopidine - analogs & derivatives (13) 13
cardiac & cardiovascular systems (11) 11
clopidogrel (11) 11
adult (9) 9
prasugrel (9) 9
double-blind method (8) 8
index medicus (8) 8
aspirin (7) 7
drug therapy (7) 7
pharmacology & pharmacy (7) 7
piperazines - administration & dosage (7) 7
research (7) 7
statistics & probability (7) 7
thiophenes - administration & dosage (7) 7
acute coronary syndromes (6) 6
cs-747 (6) 6
platelet aggregation - drug effects (6) 6
platelet aggregation inhibitors - administration & dosage (6) 6
platelet aggregation inhibitors - adverse effects (6) 6
ticlopidine - therapeutic use (6) 6
adolescent (5) 5
analysis (5) 5
antiplatelet agent (5) 5
blood platelets (5) 5
coronary heart disease (5) 5
heart attacks (5) 5
hemorrhage - chemically induced (5) 5
mortality (5) 5
piperazines - adverse effects (5) 5
piperazines - pharmacokinetics (5) 5
platelet aggregation inhibitors - therapeutic use (5) 5
resistance (5) 5
thiophenes - adverse effects (5) 5
thiophenes - pharmacokinetics (5) 5
abridged index medicus (4) 4
adenosine diphosphate (4) 4
aggregation (4) 4
antiplatelet therapy (4) 4
artery-disease (4) 4
cardiovascular (4) 4
cardiovascular disease (4) 4
dose-response relationship, drug (4) 4
intervention (4) 4
myocardial-infarction (4) 4
p2y (4) 4
percutaneous coronary intervention (4) 4
piperazines - pharmacology (4) 4
piperazines - therapeutic use (4) 4
platelet aggregation inhibitors - pharmacokinetics (4) 4
platelet aggregation inhibitors - pharmacology (4) 4
purinergic p2 receptor antagonists (4) 4
specific therapeutic activity of chemical compounds ormedicinal preparations (4) 4
studies (4) 4
thienopyridine (4) 4
thiophenes - pharmacology (4) 4
thiophenes - therapeutic use (4) 4
ticlopidine - administration & dosage (4) 4
ticlopidine - adverse effects (4) 4
wildlife management (4) 4
acute coronary syndrome (3) 3
acute coronary syndrome - drug therapy (3) 3
acute coronary syndrome - mortality (3) 3
angioplasty, balloon, coronary - adverse effects (3) 3
antagonist (3) 3
anticholesteremic agents - adverse effects (3) 3
benzodiazepines - adverse effects (3) 3
biomarkers - blood (3) 3
cardiac patients (3) 3
cardiovascular diseases - blood (3) 3
cardiovascular diseases - prevention & control (3) 3
care and treatment (3) 3
cholesterol ester transfer proteins - antagonists & inhibitors (3) 3
cholesterol, hdl - blood (3) 3
cholesterol, ldl - blood (3) 3
dosage and administration (3) 3
drug dosages (3) 3
drugs (3) 3
hypothesis testing (3) 3
increased risk (3) 3
intracluster correlation (3) 3
patient outcomes (3) 3
pharmacokinetics (3) 3
platelet inhibition (3) 3
platelet-aggregation (3) 3
reactivity (3) 3
retrospective studies (3) 3
stent thrombosis (3) 3
surgery (3) 3
thrombosis - prevention & control (3) 3
ticlopidine - pharmacology (3) 3
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (65) 65
French (6) 6
Spanish (4) 4
German (2) 2
Chinese (1) 1
Norwegian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
American Heart Journal, ISSN 0002-8703, 2015, Volume 170, Issue 6, pp. 1061 - 1069
Background Potent pharmacologic inhibition of cholesteryl ester transferase protein by the investigational agent evacetrapib increases high-density lipoprotein... 
Cardiovascular | LIPID-LEVEL MANAGEMENT | LDL CHOLESTEROL | HDL | CARDIAC & CARDIOVASCULAR SYSTEMS | ATTENUATES ATHEROSCLEROSIS | TORCETRAPIB | CORONARY-HEART-DISEASE | CETP INHIBITION | HIGH-DENSITY-LIPOPROTEIN | TRANSGENIC MICE | ARTERY-DISEASE | Cholesterol Ester Transfer Proteins - antagonists & inhibitors | Peripheral Vascular Diseases - prevention & control | Outcome Assessment (Health Care) | Humans | Middle Aged | Male | Cerebrovascular Disorders - metabolism | Cerebrovascular Disorders - prevention & control | Peripheral Vascular Diseases - metabolism | Cholesterol, LDL - blood | Female | Double-Blind Method | Risk Assessment | Coronary Artery Disease - metabolism | Coronary Artery Disease - prevention & control | Anticholesteremic Agents - adverse effects | Peripheral Vascular Diseases - diagnosis | Cerebrovascular Disorders - diagnosis | Coronary Artery Disease - diagnosis | Anticholesteremic Agents - administration & dosage | Cholesterol, HDL - blood | Benzodiazepines - administration & dosage | Benzodiazepines - adverse effects | Drug Monitoring | Cholesterol Ester Transfer Proteins - metabolism | Low density lipoproteins | Stroke | Heart attacks | Medical imaging | Mortality | Cardiovascular disease | Lipids | Triglycerides | Family medical history | Cholesterol | Studies | Lipoproteins | Ultrasonic imaging | Atherosclerosis | Blood pressure | Research centers
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2007, Volume 357, Issue 20, pp. 2001 - 2015
Antiplatelet therapy with aspirin and a thienopyridine is a key component in the management of acute coronary syndromes. This trial compared a novel, potent... 
MEDICINE, GENERAL & INTERNAL | HIGH-RISK PATIENTS | PLATELET GLYCOPROTEIN IIB/IIIA | STENT THROMBOSIS | ACUTE MYOCARDIAL-INFARCTION | UNSTABLE ANGINA | PLACEBO-CONTROLLED TRIAL | ST-SEGMENT ELEVATION | ORAL ANTIPLATELET THERAPY | ASPIRIN | INTERVENTION | Prasugrel Hydrochloride | Thiophenes - therapeutic use | Myocardial Infarction - epidemiology | Thiophenes - adverse effects | Ticlopidine - therapeutic use | Humans | Middle Aged | Acute Coronary Syndrome - mortality | Male | Angioplasty, Balloon, Coronary - adverse effects | Ticlopidine - adverse effects | Female | Stroke - epidemiology | Aspirin - therapeutic use | Thrombosis - prevention & control | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Double-Blind Method | Kaplan-Meier Estimate | Purinergic P2 Receptor Antagonists | Piperazines - therapeutic use | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Acute Coronary Syndrome - drug therapy | Prodrugs - adverse effects | Acute Coronary Syndrome - therapy | Aged | Myocardial Infarction - prevention & control | Prodrugs - therapeutic use | Hemorrhage - chemically induced | Complications and side effects | Clopidogrel | Dosage and administration | Drug therapy | Coronary heart disease | Cardiovascular disease | Heart attacks | Angina pectoris | Acute coronary syndromes
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 07/2012, Volume 60, Issue 5, pp. 388 - 396
Journal Article
American Heart Journal, ISSN 0002-8703, 2006, Volume 152, Issue 4, pp. 627 - 635
Dual antiplatelet therapy with aspirin and clopidogrel is standard for prevention of thrombotic complications of percutaneous coronary intervention (PCI).... 
CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCARDIAL-INFARCTION | TASK-FORCE | PRETREATMENT | CS-747 | RESISTANCE | INTERVENTION | ASPIRIN | ANTIPLATELET THERAPY | LY640315 | ARTERY-DISEASE | Piperazines - administration & dosage | Prasugrel Hydrochloride | Thiophenes - therapeutic use | Follow-Up Studies | Ticlopidine - therapeutic use | Humans | Thiophenes - administration & dosage | Dose-Response Relationship, Drug | Angioplasty, Balloon, Coronary - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - administration & dosage | Thrombosis - prevention & control | Platelet Aggregation Inhibitors - therapeutic use | Acute Disease | Double-Blind Method | Treatment Outcome | Piperazines - therapeutic use | Syndrome | Ticlopidine - analogs & derivatives | Myocardial Infarction - drug therapy | Thrombolytic Therapy | Coronary Disease - therapy | Coronary Disease - drug therapy | Aged | Research Design | Aggregation | Care and treatment | Usage | Blood platelets | Cardiac patients | Analysis | Physiological aspects | Clopidogrel | Research | Coronary heart disease | Transluminal angioplasty | Complications and side effects | Medical research | Aspirin | Patient outcomes | Medicine, Experimental | Heart attack | Studies | Hypotheses | Heart attacks | Consent | Acute coronary syndromes | Drug therapy | Drug dosages
Journal Article
Journal Article
Journal Article
Circulation, ISSN 0009-7322, 11/2018, Volume 138, Issue Suppl_1 Suppl 1, pp. A14025 - A14025
BackgroundPotential benefits of pharmacological CETP inhibition are likely to reflect lowering of apoB-containing lipoproteins as opposed to HDL-C raising.... 
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 6/2012, Volume 52, Issue 6, pp. 789 - 797
In TRITON-TIMI 38, levels of the prasugrel active metabolite (pras-AM) were measured in a population pharmacokinetic substudy that characterized the intrinsic... 
prasugrel | post hoc analysis | low body weight and elderly | active metabolite exposure | substudy | ACHIEVES GREATER | ANTAGONIST | CS-747 | ASPIRIN-TREATED PATIENTS | ACUTE CORONARY SYNDROMES | ANTIPLATELET AGENT | CLOPIDOGREL | POLYMORPHISMS | PLATELET INHIBITION | PHARMACOLOGY & PHARMACY | ARTERY-DISEASE | Piperazines - administration & dosage | Prodrugs - administration & dosage | Prasugrel Hydrochloride | Body Weight | Purinergic P2Y Receptor Antagonists - administration & dosage | Age Factors | Thiophenes - adverse effects | Humans | Acute Coronary Syndrome - physiopathology | Male | Purinergic P2Y Receptor Antagonists - blood | Thiophenes - administration & dosage | Thiophenes - blood | Incidence | Dose-Response Relationship, Drug | Platelet Aggregation Inhibitors - blood | Purinergic P2Y Receptor Antagonists - adverse effects | Biotransformation | Platelet Aggregation Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - pharmacokinetics | Piperazines - pharmacokinetics | Thrombosis - prevention & control | Piperazines - blood | Platelet Aggregation Inhibitors - adverse effects | Severity of Illness Index | Double-Blind Method | Hemorrhage - epidemiology | Hemorrhage - physiopathology | Purinergic P2Y Receptor Antagonists - pharmacokinetics | Piperazines - adverse effects | Acute Coronary Syndrome - drug therapy | Receptors, Purinergic P2Y12 - chemistry | Prodrugs - adverse effects | Thiophenes - pharmacokinetics | Prodrugs - pharmacokinetics | Acute Coronary Syndrome - metabolism | Models, Biological | Thrombosis - etiology | Aged | Hemorrhage - chemically induced | Methylene compounds | Research | Clinical outcomes
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 04/2008, Volume 48, Issue 4, pp. 475 - 484
Journal Article
Circulation, ISSN 0009-7322, 11/2018, Volume 138, Issue Suppl_1 Suppl 1, pp. A12636 - A12636
BackgroundThe failure of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib was associated with off target increased plasma aldosterone levels... 
Journal Article